Is deferasirox implicated in multiple organ failure in a patient with homozygous β-thalassemia?

Angiology

Volumn 62, Issue 4, 2011, Pages 346-348

  Vlachaki, Efthimia ^a,d   Chatzinikolaou, K ^b   Bekiari, E ^a   Klonizakis, F ^a   Tsapas, A ^a,c  

^a Aristotle University of Thessaloniki   (Greece)

^b Agios Pavlos General Hospital   (Greece)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NONE   (Greece)

Author keywords

thalassemia; deferasirox; sepsis

Indexed keywords

DEFERASIROX; DEFERIPRONE; FERRITIN; PEGINTERFERON;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ADULT; ARTICLE; BETA THALASSEMIA; CASE REPORT; CAUSE OF DEATH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FERRITIN BLOOD LEVEL; FEVER; HEART ARREST; HOMOZYGOTE; HUMAN; HYPOGLYCEMIA; IRON CHELATION; MALE; MENTAL INSTABILITY; METABOLIC ACIDOSIS; MULTIPLE ORGAN FAILURE; NEUTROPENIA; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; CHELATION THERAPY; FATAL OUTCOME; HUMANS; IRON CHELATING AGENTS; MALE; MULTIPLE ORGAN FAILURE; RISK FACTORS; TRIAZOLES;

EID: 79953879022     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710394160     Document Type: Article

References (19)

1. Borgna-Pignatti C., Cappellini MD, De Stefano P., et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006 ; 107 (9). 3733-3737.
2. Ladis V., Chouliaras G., Berdoukas V., et al. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. Eur J Haematol. 2010 ; 85 (4). 335-344.
3. Vlachaki E., Ioannidou-Papagiannaki E., Tziomalos K., et al. Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy. Eur J Haematol. 2007 ; 78 (1). 48-51. (Pubitemid 46018558)
4. Ruffo GB, Borsellino Z., Cuccia L., Marocco MR, Gagliardotto F., Tarantino R. Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI. Clin Drug Investig. 2010 ; 30 (4). 267-273.
5. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010 ; 115 (12). 2364-2371.
6. Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol. 2008 ; 83 (5). 398-402. (Pubitemid 351614754)
7. Kontoghiorghes GJ Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin. 2008 ; 32 (6). 608-615.
8. Kontoghiorghes GJ Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin. 2008 ; 32 (6). 1-15. (Pubitemid 351264512)
9. Porter JB, Taher AT, Cappellini MD, Vichinsky EP Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin. 2008 ; 32 (1-2). 1-15.]. Hemoglobin. 2008 ; 32 (6). 601-607.
10. Briguori C., Airoldi F., D'Andrea D., et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007 ; 115 (10). 1211-1217. (Pubitemid 46594764)
11. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995 ; 23 (10). 1638-1652.
12. Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med. 2007 ; 35 (10). 2262-2267. (Pubitemid 47476221)
13. Miller SI, Wallace RJ Jr, Musher DM, Septimus EJ, Kohl S., Baughn RE Hypoglycemia as a manifestation of sepsis. Am J Med. 1980 ; 68 (5). 649-654. (Pubitemid 10096029)
14. Kato GJ, Taylor JGt. Pleiotropic effects of intravascular haemolysis on vascular homeostasis. Br J Haematol. 2010 ; 148 (5). 690-701.
15. Kontoghiorghes GJ Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf. 2010 ; 9 (4). 633-641.
16. Papadopoulos N., Vasiliki A., Aloizos G., Tapinis P., Kikilas A. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. Ann Pharmacother. 2010 ; 44 (1). 219-221.
17. Messa E., Carturan S., Maffe C., et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010 ; 95 (8). 1308-1316.
18. Liu SF, Malik AB NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol. 2006 ; 290 (4). L622 - L645. (Pubitemid 43738989)
19. Li X., Su J., Cui X., Li Y., Barochia A., Eichacker PQ Can we predict the effects of NF-kappaB inhibition in sepsis? Studies with parthenolide and ethyl pyruvate. Expert Opin Investig Drugs. 2009 ; 18 (8). 1047-1060.